全文获取类型
收费全文 | 70743篇 |
免费 | 4494篇 |
国内免费 | 266篇 |
专业分类
耳鼻咽喉 | 1110篇 |
儿科学 | 2026篇 |
妇产科学 | 1326篇 |
基础医学 | 7827篇 |
口腔科学 | 1451篇 |
临床医学 | 6964篇 |
内科学 | 14609篇 |
皮肤病学 | 1113篇 |
神经病学 | 6889篇 |
特种医学 | 2485篇 |
外国民族医学 | 5篇 |
外科学 | 12344篇 |
综合类 | 845篇 |
一般理论 | 94篇 |
预防医学 | 5873篇 |
眼科学 | 1371篇 |
药学 | 4537篇 |
中国医学 | 111篇 |
肿瘤学 | 4523篇 |
出版年
2023年 | 352篇 |
2022年 | 324篇 |
2021年 | 1763篇 |
2020年 | 928篇 |
2019年 | 1550篇 |
2018年 | 1811篇 |
2017年 | 1306篇 |
2016年 | 1338篇 |
2015年 | 1474篇 |
2014年 | 2274篇 |
2013年 | 3204篇 |
2012年 | 4852篇 |
2011年 | 5033篇 |
2010年 | 2760篇 |
2009年 | 2450篇 |
2008年 | 4451篇 |
2007年 | 4712篇 |
2006年 | 4569篇 |
2005年 | 4546篇 |
2004年 | 4288篇 |
2003年 | 3950篇 |
2002年 | 3667篇 |
2001年 | 558篇 |
2000年 | 486篇 |
1999年 | 634篇 |
1998年 | 743篇 |
1997年 | 668篇 |
1996年 | 592篇 |
1995年 | 522篇 |
1994年 | 511篇 |
1993年 | 430篇 |
1992年 | 380篇 |
1991年 | 378篇 |
1990年 | 306篇 |
1989年 | 289篇 |
1988年 | 280篇 |
1987年 | 261篇 |
1986年 | 272篇 |
1985年 | 365篇 |
1984年 | 430篇 |
1983年 | 360篇 |
1982年 | 513篇 |
1981年 | 483篇 |
1980年 | 449篇 |
1979年 | 205篇 |
1978年 | 272篇 |
1977年 | 255篇 |
1976年 | 200篇 |
1975年 | 219篇 |
1973年 | 183篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
11.
12.
James Milligan Joseph Lee Matt Smith Lindsay Donaldson Peter Athanasopoulos Kent Bassett-Spiers 《The journal of spinal cord medicine》2020,43(2):223-233
Context: Persons with spinal cord injury (SCI) experience significant challenges when they access primary care and community services.Design: A provincial summit was held to direct research, education, and innovation for primary and community care for SCI.Setting: Toronto, Ontario, Canada.Participants: Key stakeholders (N?=?95) including persons with SCI and caregivers, clinicians from primary care, rehabilitation, and specialized care, researchers, advocacy groups, and policy makers.Methods: A one-day facilitated meeting that included guest speakers, panel discussions and small group discussions was held to generate potential solutions to current issues related to SCI care and to foster collaborative relationships to advance care for SCI. Perspectives on SCI management were shared by primary care, neurosurgery, rehabilitation, and members of the SCI communityOutcome Measures: Discussions were focused on five domains: knowledge translation and dissemination, application of best practices, communication, research, and patient service accessibility.Results: Summit participants identified issues and prioritized solutions to improve primary and community care including the creation of a network of key stakeholders to enable knowledge creation and dissemination; an online repository of SCI resources, integrated health records, and a clinical network for SCI care; development and implementation of strategies to improve care transitions across sectors; implementation of effective care models and improved access to services; and utilization of empowerment frameworks to support self-management.Conclusions: This summit identified priorities for further collaborative efforts to advance SCI primary and community care and will inform the development of a provincial SCI strategy aimed at improving the system of care for SCI. 相似文献
13.
14.
Nicole D. Facompre Pavithra Rajagopalan Varun Sahu Alexander T. Pearson Kathleen T. Montone Claire D. James Frederico O. Gleber-Netto Gregory S. Weinstein Jalal Jalaly Alexander Lin Anil K. Rustgi Hiroshi Nakagawa Joseph A. Califano Curtis R. Pickering Elizabeth A. White Bradford E. Windle Iain M. Morgan Roger B. Cohen Phyllis A. Gimotty Devraj Basu 《International journal of cancer. Journal international du cancer》2020,147(11):3236-3249
15.
Bhavana Pothuri Allison L. Brodsky Joseph A. Sparano Stephanie V. Blank Mimi Kim Dawn L. Hershman Amy Tiersten Brian F. Kiesel Jan H. Beumer Leonard Liebes Franco Muggia 《Cancer chemotherapy and pharmacology》2020,85(4):741-751
Poly(ADP-ribosyl) polymerases (PARPs) are nuclear enzymes with roles in DNA damage recognition and repair. PARP1 inhibition enhances the effects of DNA-damaging agents like doxorubicin. We sought to determine the recommended phase two dose (RP2D) of veliparib with pegylated liposomal doxorubicin (PLD) in breast and recurrent gynecologic cancer patients. Veliparib and PLD were administered in a standard phase 1, 3 + 3 dose-escalation design starting at 50 mg veliparib BID on days 1–14 with PLD 40 mg/mg2 on day 1 of a 28-day cycle. Dose escalation proceeded in two strata: A (prior PLD exposure) and B (no prior PLD exposure). Patients underwent limited pharmacokinetic (PK) sampling; an expansion PK cohort was added. 44 patients with recurrent ovarian or triple negative breast cancer were enrolled. Median age 56 years; 23 patients BRCA mutation carriers; median prior regimens four. Patients received a median of four cycles of veliparib/PLD. Grade 3/4 toxicities were observed in 10% of patients. Antitumor activity was observed in both sporadic and BRCA-deficient cancers. Two BRCA mutation carriers had complete responses. Two BRCA patients developed oral squamous cell cancers after completing this regimen. PLD exposure was observed to be higher when veliparib doses were > 200 mg BID. The RP2D is 200 mg veliparib BID on days 1–14 with 40 mg/m2 PLD on day 1 of a 28-day cycle. Anti-tumor activity was seen in both strata. However, given development of long-term squamous cell cancers and the PK interaction observed, efforts should focus on other targeted combinations to improve efficacy. 相似文献
16.
17.
18.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献
19.
20.
Naveen B.S. M.T. Mohan J. Tharayil S.T. Joseph 《International journal of oral and maxillofacial surgery》2021,50(8):1003-1008
A local pedicled vascularized bone flap can prevent the morbidity and cost of free bone flap surgery in small segmental bone defects or long cartilaginous defects of the head and neck. Such flaps can also be useful in patients who are high risk for surgery. The periosteal vascularity of the mandible can be used to design islanded facial artery-based bone flaps, which can be utilized to that extent. Two patients with a small segmental mandibulectomy defect and one patient with a long cricotracheal resection defect underwent reconstruction using three different designs of islanded facial artery osteomyomucosal/osseous flap (iFOMM). The patients had a minimum follow-up period of 18 months. All flaps were successful, with satisfactory healing and without any functional deficit or disease at last follow-up. 相似文献